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Introduction
Chronic Heart Failure (CHF) is a growing pub-
lic health problem impacting heavily on patient sur-
vival, quality of life and healthcare costs. Due
mainly to coronary artery disease [1], hypertension,
valve disease and cardiomyopathies, it is character-
ized by (a) shortness of breath at rest or during ex-
ertion, and fatigue; (b) signs of fluid retention such
as pulmonary congestion or ankle swelling; (c) and
an objective evidence of an abnormality of the struc-
ture or function of the heart at rest [2]. 
The incidence and prevalence (2-3%; 10-20%
after 75 years of age) are clearly increasing in in-
dustrialized countries [2, 3]. According to the Euro-
pean Society of Cardiology roughly 15 million pa-
tients were diagnosed with CHF out of a population
of 900 million people. 
However, despite considerable investment in re-
search and guidelines dissemination by several scien-
tific societies, the treatment gap of CHF continues to
widen between evidence-based approach and practice
reality across the continuum of care, resulting in an
unsustainable high morbidity and mortality along
with an increasing economic and social burden [4-8].
We herein present the design and the aims of
The T.O.S.CA. Project (Trattamento Ormonale dello
Scompenso CArdiaco): an Italian multicenter initia-
tive aiming to explore the CHF “metabolic patho-
physiological model” and to improve the quality of
care through the implementation of a dedicated con-
tinuing medical educational program. 
Research
Despite different hypotheses, no single patho-
physiologic paradigm of CHF has been definitively
established. One logical explanation of the inability
to define the syndrome of CHF in precise mechanis-
tic models is that the clinical syndrome of CHF al-
most certainly represents the summation of multiple
anatomic, functional, and biological alterations that
interact together in an complex way. Thus, it is not
surprising that investigators employing simple mod-
els in an attempt to describe the syndrome of HF
have failed [9].
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Despite recent and exponential improvements in diagnos-
tic-therapeutic pathways, an existing “GAP” has been re-
vealed between the “real world care” and the “optimal care”
of patients with chronic heart failure (CHF). We present the
T.O.S.CA. Project (Trattamento Ormonale dello Scompenso
CArdiaco), an Italian multicenter initiative involving different
health care professionals and services aiming to explore the
CHF “metabolic pathophysiological model” and to improve
the quality of care of HF patients through research and con-
tinuing medical education.
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Nowadays, the most accepted hypothesis ex-
plaining CHF pathophysiology and its progression
is the “neurohormonal model”. According to this
paradigm, heart failure progresses as a result of the
overexpression of biologically active molecules that
exert toxic effects on the heart and circulation. A va-
riety of molecules including norepinephrine, an-
giotensin II, endothelin, aldosterone, and tumor
necrosis factor have been implicated as some of the
factors that contribute to disease progression in the
failing heart [9].
The evidence in support of this point of view is
derived from many experimental and clinical studies
showing that overexpression of active molecules re-
ported above can contribute to disease progression in-
dependently of the hemodynamic status of the patient
and that antagonizing neurohormones improve clini-
cal outcomes of patients with CHF. Indeed, the “neu-
rohormonal axis” is the main target of medical treat-
ments proved to be efficacious in CHF, such as ACE-
I, beta blockers and spironolacton/eplerenon [10]. 
However, the “neurohormonal model” displayed
several pitfalls. A complete inhibition of hormonal
axes involved in CHF progression is difficult to ob-
tain for dose-limiting effects of drugs and also for
alternative metabolic pathways that are not antago-
nized by conventional therapy. On the other hand,
other unknown molecular interactions potentially
involved in the progression of CHF are likely to be
involved. 
Despite the effectiveness of the neurohormonal
model to explain disease progression and the many
insights that it provided for the development of new
therapies, there is an increasing clinical evidence
that suggests that our current models fail to com-
pletely explain disease progression.
The observation that the survival curves become
parallel following neurohormonal antagonism sug-
gests that there may be an attenuation or loss of ef-
fectiveness of neurohormonal antagonism as heart
failure progresses. Thus, neurohormonal models
may be necessary but not sufficient to explain all the
aspects of disease progression of the failing heart.
Based on these observations and on the poor
prognosis despite optimal therapies, alternative
mechanisms that contribute to CHF progression are
being actively explored. In this regard, recent evi-
dence suggests that a metabolic imbalance occurs in
CHF, characterized by a predominance of the cata-
bolic status over anabolic drive. The most impres-
sive example is seen in end-stage CHF known as
“cardiac cachexia” characterized by sustained
weight loss, particularly lean mass, and rapid deteri-
oration of clinical conditions, attributed to a preva-
lence of catabolic pathways. Whether such hor-
monal imbalance is a mere epiphenomenon or an
important pathophysiological mechanism in CHF
progression is still matter of debate. The main evi-
dence concerning anabolic deficiencies in CHF pa-
tients is described in a recent study by Jankowska et
al. [11]; specifically, deficit of each anabolic axis
(adrenal, gonadal and somatotropic axes) represents
an independent marker of poor outcome in CHF pa-
tients and the coexistence of more than one defi-
ciency identifies a subgroup of patients with a
higher mortality. 
The most involved hormonal axes include
growth hormone (GH), its tissue effector insulin-
like growth factor-1 (IGF-1), thyroid hormone, in-
sulin and anabolic steroids. Taken together, these al-
terations could be recognised as a multiple hormonal
and metabolic deficiency syndrome (MHD) in HF
patients. MHD bears a significant impact on cardiac
performance and HF progression [12]. 
These considerations provide novel and interest-
ing opportunities including: (a) The identification of
new prognostic markers; (b) The implementation of
knowledge about multiple hormonal deficiency syn-
drome (MHD); (c) The basis for new therapeutic ap-
proaches in this regards our group has some recent
experiences in GH replacement therapy.
Chief among the hormonal systems the GH/IGF-
1 axis play a pivotal role, being the most powerful
anabolic pathway in the human body. In fact, GH
and IGF-1 are essential for preserving both cardiac
morphology and performance in adult life. The find-
ing of low IGF-1 levels in CHF patients is relevant
for many reasons. First, individuals with low IGF-1
levels undergo cardiovascular alterations that are
corrected by replacement therapy; in this regards our
group has some recent experiences in GH replace-
ment therapy [13]. Second, large population-based
studies show that a low level of IGF-1 is predictive
of HF. Finally, low IGF-1 levels are associated with
reduced skeletal muscle performance and endothe-
lial dysfunction [14].
Thus, study of GH/IGF-1 axis represents the
main topic of T.O.S.CA. investigations.
Preliminary insights from T.O.S.CA. project
about clinical status and cardiovascular performance
in patients with low IGF-1 levels were presented at
the recent European Congress of Cardiology [15].
Aims of T.O.S.CA. Project - Research:
The T.O.S.CA. project therefore represents a
unique opportunity to create a large database from
several centers both in Italy and abroad in order to
respond to some fundamental pathophysiological
questions. First, what are the reference values of the
main anabolic axes in a large Italian CHF popula-
tion, coming from different regions of our country?
What is the actual prevalence of multiple hormone
deficiencies in CHF? Second, we will evaluate
whether anabolic deficiencies identify subgroups of
CHF patients with worse clinical status and more
impaired LV architecture, function and cardiopul-
monary performance. Third and more importantly,
we will be able to address the question of whether
single or multiple hormone deficiencies affect heart
failure progression and poor outcome.
Smaller case-control studies will address more
specific topics such as the relation between direct
assessment of myocardial ultrastructure and gene
expression profile, and the anabolic/catabolic bal-
ance, evaluating myocardial biopsies of CHF pa-
tients undergoing cardiac surgery.
Education
Despite the recent and exponential improve-
ments in diagnostic-therapeutic pathways, an exist-
ing “GAP” has been revealed from the “real world
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care” and the “optimal care” of patients with CHF
[16-28]. A recent Italian multicentric population-
based study has confirmed the “GAP” in health sta-
tus among socioeconomic groups particularly evi-
dent for CHF characterized by an excess of unnec-
essary hospitalization [29]. 
In Italy the educational health program (defined
as E.C.M: Continuing Medical Education) consists
of theoretical and practical activities promoted by
agencies and scientific societies and regulated by
specific legislation (DLgs 229/99 and L. 238/00). In
particular, the purpose of the T.O.SCA project edu-
cational branch is to improve the quality of care of
CHF patients (timeliness, efficiency and effective-
ness) in different clinical settings. It consists of a spe-
cialized E.C.M.-meta-model designed by a dedicated
multidisciplinary team and applied through an inten-
sive three phases educational year (Fig. 1).
Phase 1: Pre-T.O.SCA: (a) Selection of partici-
pant hospitals and investigators; (b) Investigators’
training (meeting-tutorial-web site); (c) Presentation
and beginning of the project; (d) Analysis “status
quo” of actual diagnostic-therapeutic pathways. Data
(i.e. medical history, symptoms and signs, electrocar-
diographic, chest X Ray, echo-Doppler and other
imaging results, in -hospital treatment disposition,
follow-up) will to be collected on a standard case-re-
port form and then forwarded to the T.O.S.CA. reg-
istry coordinating center for analysis. Quality of care
is going to be assessed by measuring the use of “key
indicators” as for current ESC guidelines. 
Phase 2: T.O.SCA Implementation: (e) Improve-
ment of adhesion to the guidelines through dedi-
cated tools;(f) Weekly-monthly meeting (ECM) and
quality control.
Phase 3: post-T.O.SCA: (g) Analysis post guide-
lines implementation. (h) Presentation and discus-
sion of results.
Care
The actual picture of CHF in Europe and Italy is
predominantly represented by continuous acute hos-
pital admissions, poor prognosis, an ongoing drain of
health care expenditure and discomfort for the pa-
tients and care givers [30-33]. Thus, in order to opti-
mize the medical management, reduce the hospital-
ization and readmission rate, improve and maintain
optimum quality of life, and balance the cost/benefits
ratio, the European Society of Cardiology guidelines
recommend the implementation of structured multi-
sciplinary CHF disease-management program (Class
of recommendation I, level of evidence A) taking
into account patient needs, financial resources, avail-
able personnel, and administrative policies [2]. In
this regard the T.O.S.CA. team has developed a
meta-model of structured CHFMG (Chronic Heart
Failure Management Program) (Fig. 2) on the area
of Amalfi Coast in Southern
Italy as a continuum between
the community hospitals and
the territorial health system
serving 110.000 habitants
among 13 cities. The CHF
out-patient clinic represents
the platform of the Amalfi
Coast CHFMG, directed by
clinical cardiologist and co-
ordinated by registered nurse,
along with multidisciplinary
team. Patient-first contact
with CHFMG may be during
hospitalization or as specific
request from primary care
physician. During the first
outpatient visit the cardiolo-
gist will assess the clinical
status and current therapy,
design an effective follow-up
strategy such as ambulatory
care, day service, day hospi-
tal [35-37]. A tertiary level
hospital constitutes the refer-
ral center for invasive and
surgical treatments (revascu-
larization procedures, valvu-





lar assist devices). Cardiac
rehabilitation and genetic
counseling are also provided
when indicated. Figure 1.
201
THE T.O.S.CA. PROJECT: RESEARCH, EDUCATION AND CARE
Genetic Counselling and “Phenotyping”
In this regard, genetic counseling represents an
important preliminary part of the study cohort selec-
tion process. Indeed, as mentioned above, the clini-
cal syndrome of CHF represent the “summa” of
multiple anatomic, functional, and molecular alter-
ations that contribute to initiate (preclinical phase),
manifest (onset), and worsen (progression to end
stage) HF. On this ground, the clinical attempt to de-
fine “subgroup of CHF syndromes” helps to better
characterize the clinical phenotype. In clinical prac-
tice, this will be realized by:
(a) the study of the family tree (sudden deaths,
transplants, cardiomyopathies/myopathies); (b) clin-
ical exclusion of metabolic-mitochondrial (sys-
temic), and neuromuscular involvement (“clinical
red flags”); (c) integrated imaging (new echo tech-
nologies and MRI); (d) phenotype-guided molecular
analysis (in selected cases).
Finally, the phenotype characterization will rec-
ognize these groups:
(1) ischemic cardiomyopathy, (2) familial di-
lated cardiomyopathy, (3) non familial, dilated car-
diomyopathy (idiopathic), (4) myocarditis and au-
toimmune cardiomyopathy
Exclusion criteria will be: diagnosis of neuro-
muscular (ie: dystrophynopathy, laminopathy, etc),
mitochondrial (i.e.: MELAS and MERRF syn-
drome), and toxic (i.e. cocaine or pheocromocy-
toma) cardiomyopathy [38-39]. 
Conclusions
In conclusion, the T.O.S.CA. project may repre-
sent a challenging “learning by doing” experience
involving different health care professionals and ser-
vices and aiming to explore the CHF “metabolic
pathophysiological model” and to improve the qual-
ity of care of CHF patients through research and
continuing medical education.
Riassunto
Nonostante i recenti ed esponenziali progressi
ottenuti nel campo diagnostico-terapeutico, è stato
rilevato un “GAP” esistente tra la pratica clinica e
la gestione ideale dei pazienti con Insufficienza Car-
diaca Cronica (ICC). In questo lavoro viene presen-
tato il progetto T.O.S.CA. (Trattamento Ormonale
dello Scompenso CArdiaco), un’iniziativa italiana
multicentrica che coinvolge differenti professionisti
e servizi sanitari finalizzata all’esplorare il cosid-
detto “modello fisiopatologico e metabolico” e nel
migliorare la qualità del trattamento dei pazienti af-
fetti da ICC attraverso protocolli di ricerca ed ag-
giornamento medico continuo.
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